Alnylam (ALNY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Fintel reports that on July 21, 2025, Truist Securities initiated coverage of Alnylam Pharmaceuticals (NasdaqGS:ALNY) with a Buy recommendation. Analyst Price Forecast Suggests 6.19% Upside As of July ...

Insights from analysts' 12-month price targets are revealed, presenting an average target of $357.7, a high estimate of $404.00, and a low estimate of $325.00. Marking an increase of 10.61%, the ...

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he ...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2025 on Thursday, July ...

Alnylam Pharmaceuticals’ Amvuttra (vutrisiran) has been approved by the Medicines and Healthcare products Regulatory Agency ...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, ...

Shares of Charles River Laboratories International Inc. advanced 9.06% to $163.36 Tuesday, on what proved to be an all-around ...

Alnylam (Nasdaq: ALNY) has secured expanded UK regulatory approval for Amvuttra (vutrisiran), broadening its indication to include treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) in adults ...

Detailed price information for United Therapeutic (UTHR-Q) from The Globe and Mail including charting and trades.

There is decreased risk of all-cause and CV mortality in patients with transthyretin amyloidosis with cardiomyopathy treated with vutrisiran.

In a report released today, Jessica Fye from J.P. Morgan maintained a Sell rating on Moderna, with a price target of $26.00. The company’s shares closed yesterday at $32.06. Ele ...